Funder
National Natural Science Foundation of China
Research Foundation
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference39 articles.
1. Global burden of human papillomavirus and related diseases;Forman;Vaccine,2012
2. Bruni L AG, Serrano B, Mena M, Gómez D, Muñoz J, et al. ICO/IARC information centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary Report 17 June 2019 [Date Accessed]. https://hpvcentre.net/statistics/reports/XWX.pdf?t=1592755153991
3. Worldwide burden of cancer attributable to HPV by site, country and HPV type;de Martel;Int J Cancer,2017
4. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women;Joura;The New Engl J Med,2015
5. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial;Paavonen;Lancet,2007
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial;Science Bulletin;2023-10
2. Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China;Human Vaccines & Immunotherapeutics;2023-07-30
3. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China;Frontiers in Immunology;2023-03-13
4. Human Papillomavirus Vaccines;Plotkin's Vaccines;2023
5. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial;The Lancet Infectious Diseases;2022-12